ARQT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ARQT is a good long-term buy for a beginner with $50,000-$100,000 to invest, but only as a measured position rather than a full-size aggressive purchase. The stock has supportive fundamentals, strong revenue growth, and broadly positive Wall Street sentiment, while the current price is still below the main analyst targets. Because the user is impatient and does not want to wait for an ideal entry, the current level is acceptable for initiating a position now.
ARQT is in a weak short-term trend but not a broken long-term setup. The MACD histogram is negative and still expanding lower, which signals near-term bearish momentum. RSI_6 at 24.749 suggests the stock is oversold/near oversold, which can support a rebound. Moving averages are converging, pointing to a possible trend inflection. Key levels to watch are support at 20.95 and 19.987, with resistance at 22.508 and 24.067. With the stock closing at 20.75, price is sitting just above support, making this a reasonable entry point for a patient long-term buyer.
["Q1 2026 net product revenue of $105.4M, up 65% from Q1 2025.", "Full-year revenue guidance of $480M-$495M was maintained despite seasonal challenges.", "Gross margin improved to 90.72%, showing strong product economics.", "Analyst targets remain mostly in the mid-$30s, well above the current price.", "Congress trading shows 1 purchase and 0 sales in the last 90 days, suggesting positive institutional/political attention."]
["Net income remains negative at -$11.3M and EPS declined year over year.", "R&D expenses increased due to a $10M milestone obligation for ARQ-234.", "Insiders are selling, and selling activity increased 100.73% over the last month.", "Short-term technical momentum is weak, with a negative and expanding MACD histogram.", "Stock trend data suggests limited near-term upside and some weakness over the next week."]
In Q1 2026, Arcutis showed very strong top-line growth, with revenue rising to $105.398M, up 60.07% YoY. This is the latest quarter season reported. Gross margin improved to 90.72%, which is excellent and supports scalability. However, profitability remains negative, with net income at -$11.295M and EPS at -0.09, both worse year over year. Overall, the quarter was strong on growth and margin expansion, but still not profitable.
Wall Street remains constructive overall. Recent analyst actions mostly involved reiterating Buy/Outperform/Overweight ratings while raising price targets into the $34-$35 range. Morgan Stanley recently trimmed its target slightly to $34 from $35 but kept Overweight. Guggenheim, TD Cowen, H.C. Wainwright, and Mizuho remain positive, with several citing strong Q4 results, better-than-expected sales, and raised guidance. The pros view is that Zoryve commercialization is progressing well and revenue growth is strong. The cons view is that some target prices have been nudged lower recently, reflecting more tempered upside expectations after the move higher.
